44 related articles for article (PubMed ID: 38423630)
1. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.
Hara S; Sakai D; Ikemura K; Shintani T; Yamamoto T; Satoh T; Okuda M
Anticancer Res; 2024 Mar; 44(3):1219-1226. PubMed ID: 38423630
[TBL] [Abstract][Full Text] [Related]
2. Impact of KRAS
Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.
Dayyani F; Balangue J; Valerin J; Keating MJ; Zell JA; Taylor TH; Cho MT
Clin Colorectal Cancer; 2024 Mar; 23(1):67-72. PubMed ID: 38103947
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A
BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951
[TBL] [Abstract][Full Text] [Related]
7. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
[TBL] [Abstract][Full Text] [Related]
9. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T; Yamamoto Y; Kotaka M; Masuishi T; Tsuji Y; Shoji H; Hirata K; Tsuduki T; Makiyama A; Izawa N; Takahashi N; Tsuda M; Yasui H; Ohta T; Kito Y; Otsu S; Hironaka S; Yamazaki K; Boku N; Hyodo I; Yoshimura K; Muro K
Target Oncol; 2024 Mar; 19(2):181-190. PubMed ID: 38427280
[TBL] [Abstract][Full Text] [Related]
11. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
[TBL] [Abstract][Full Text] [Related]
12. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
13. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Miyamoto Y; Lenz HJ; Baba H
Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
[No Abstract] [Full Text] [Related]
15. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Cheung WY; Kavan P; Dolley A
Curr Oncol; 2020 Oct; 27(5):e451-e458. PubMed ID: 33173384
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients.
Lee V; Parkinson R; Zahurak M; Cope L; Cercek A; Verheul H; Gootjes E; Lenz HJ; Iqbal S; Jones P; Baylin S; Rami V; Ahuja N; El Khoueiry A; Azad NS
Int J Cancer; 2024 May; 154(10):1794-1801. PubMed ID: 38312102
[TBL] [Abstract][Full Text] [Related]
17. Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis.
Azeredo-da-Silva ALF; de Jesus VHF; Agirrezabal I; Brennan VK; Carion PL; Amoury N; Vetromilla BM; Zanotto BS; Shergill S; Ziegelmann PK
Adv Ther; 2024 Apr; 41(4):1606-1620. PubMed ID: 38407790
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.
Koganemaru S; Fuchigami H; Yamashita H; Morizono C; Sunakawa H; Kawazoe A; Nakamura Y; Kuboki Y; Shitara K; Yano T; Doi T; Yasunaga M
Clin Pharmacol Ther; 2024 Jan; 115(1):62-70. PubMed ID: 37803526
[TBL] [Abstract][Full Text] [Related]
19. Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience.
Tong D; Wang L; Mendis J; Essapen S
Curr Oncol; 2021 Jun; 28(3):2260-2269. PubMed ID: 34207352
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Zhu M; Sonbol MB; Yoon HH
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):154-155. PubMed ID: 33508243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
